{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T12:14:29Z","timestamp":1769516069350,"version":"3.49.0"},"reference-count":8,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jcf.2021.02.005","type":"journal-article","created":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T10:28:01Z","timestamp":1614680881000},"page":"e124-e128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Chronic incretin-based therapy in cystic fibrosis-related diabetes: A tale of 3 patients treated with sitagliptin for over 5 years"],"prefix":"10.1016","volume":"20","author":[{"given":"Samuel T.","family":"Olatunbosun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jcf.2021.02.005_bib0001","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2337\/dc09-0586","article-title":"Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality","volume":"32","author":"Moran","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcf.2021.02.005_bib0002","doi-asserted-by":"crossref","DOI":"10.1177\/1179551419851770","article-title":"Cystic Fibrosis-Related Diabetes: pathophysiology and therapeutic challenges","volume":"12","author":"Kelsey","year":"2019","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"issue":"12","key":"10.1016\/j.jcf.2021.02.005_bib0003","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2337\/dc10-1768","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"10.1016\/j.jcf.2021.02.005_bib0004","article-title":"Cystic fibrosis related diabetes: medical management","volume":"18","author":"Ode","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"Suppl 2","key":"10.1016\/j.jcf.2021.02.005_bib0005","article-title":"Hypoglycemia in cystic fibrosis: prevalence, impact and treatment","volume":"18","author":"Moheet","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2021.02.005_bib0006","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jcf.2011.11.001","article-title":"Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus","volume":"11","author":"Hillman","year":"2012","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2021.02.005_bib0007","first-page":"501","article-title":"Use of Dipeptidyl Peptidase-4 Inhibitors in a Subset of Patients with Cystic Fibrosis Related Diabetes","volume":"6","author":"Patel","year":"2015","journal-title":"J Diabetes Metab"},{"issue":"3","key":"10.1016\/j.jcf.2021.02.005_bib0008","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/MEG.0b013e3282f36d04","article-title":"The changing face of the exocrine pancreas in cystic fibrosis: the correlation between pancreatic status, pancreatitis and cystic fibrosis genotype","volume":"20","author":"Augarten","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199321000400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199321000400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:46:18Z","timestamp":1761601578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199321000400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":8,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S1569199321000400"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2021.02.005","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic incretin-based therapy in cystic fibrosis-related diabetes: A tale of 3 patients treated with sitagliptin for over 5 years","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2021.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}